Unknown

Dataset Information

0

Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.


ABSTRACT: TNP-2198, a stable conjugate of a rifamycin pharmacophore and a nitroimidazole pharmacophore, has been designed, synthesized, and evaluated as a novel dual-targeted antibacterial agent for the treatment of microaerophilic and anaerobic bacterial infections. TNP-2198 exhibits greater activity than a 1:1 molar mixture of the parent drugs and exhibits activity against strains resistant to both rifamycins and nitroimidazoles. A crystal structure of TNP-2198 bound to a Mycobacterium tuberculosis RNA polymerase transcription initiation complex reveals that the rifamycin portion of TNP-2198 binds to the rifamycin binding site on RNAP and the nitroimidazole portion of TNP-2198 interacts directly with the DNA template-strand in the RNAP active-center cleft, forming a hydrogen bond with a base of the DNA template strand. TNP-2198 is currently in Phase 2 clinical development for the treatment of Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis.

SUBMITTER: Ma Z 

PROVIDER: S-EPMC8958509 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.

Ma Zhenkun Z   He Shijie S   Yuan Ying Y   Zhuang Zhijun Z   Liu Yu Y   Wang Huan H   Chen Jing J   Xu Xiangyi X   Ding Charles C   Molodtsov Vadim V   Lin Wei W   Robertson Gregory T GT   Weiss William J WJ   Pulse Mark M   Nguyen Phung P   Duncan Leonard L   Doyle Timothy T   Ebright Richard H RH   Lynch Anthony Simon AS  

Journal of medicinal chemistry 20220217 6


TNP-2198, a stable conjugate of a rifamycin pharmacophore and a nitroimidazole pharmacophore, has been designed, synthesized, and evaluated as a novel dual-targeted antibacterial agent for the treatment of microaerophilic and anaerobic bacterial infections. TNP-2198 exhibits greater activity than a 1:1 molar mixture of the parent drugs and exhibits activity against strains resistant to both rifamycins and nitroimidazoles. A crystal structure of TNP-2198 bound to a <i>Mycobacterium tuberculosis</  ...[more]

Similar Datasets

| S-EPMC4651866 | biostudies-literature
| S-EPMC9679668 | biostudies-literature
| S-EPMC9679994 | biostudies-literature
| S-EPMC3719725 | biostudies-literature
| S-EPMC7933538 | biostudies-literature
| S-EPMC6429600 | biostudies-literature
| S-EPMC5585216 | biostudies-literature
| S-EPMC11443207 | biostudies-literature
| S-EPMC3817215 | biostudies-literature
2022-11-09 | PXD033128 | Pride